| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | ELI LILLY & Co | 71,604,696 | 7.5% | EDGAR |
| SC 13G/A | 2024-02-09 | PNC FINANCIAL SERVICES GROUP, INC. | ELI LILLY & Co | 51,540,105 | 5.4% | EDGAR |
| SC 13G/A | 2024-01-29 | BlackRock Inc. | ELI LILLY & Co | 64,376,027 | 6.8% | EDGAR |
| SC 13G/A | 2024-01-26 | LILLY ENDOWMENT INC | ELI LILLY & Co | 99,768,810 | 10.5% | EDGAR |
| SC 13D/A | 2023-08-14 | ELI LILLY & Co | Sigilon Therapeutics, Inc. | 100 | 100.0% | EDGAR |
| SC 13D | 2023-07-07 | ELI LILLY & Co | Sigilon Therapeutics, Inc. | 1,008,830 | 40.3% | EDGAR |
| SC 13G/A | 2023-02-10 | PNC FINANCIAL SERVICES GROUP, INC. | ELI LILLY & Co | 51,829,873 | 5.2% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | ELI LILLY & Co | 73,429,863 | 7.7% | EDGAR |
| SC 13G/A | 2023-02-01 | BlackRock Inc. | ELI LILLY & Co | 65,467,793 | 6.9% | EDGAR |
| SC 13G/A | 2023-01-27 | ELI LILLY & Co | AC Immune SA | 3,615,328 | 4.3% | EDGAR |
| SC 13G/A | 2023-01-27 | ELI LILLY & Co | PRECISION BIOSCIENCES INC | 3,762,190 | 3.4% | EDGAR |
| SC 13G/A | 2023-01-25 | LILLY ENDOWMENT INC | ELI LILLY & Co | 102,948,810 | 10.8% | EDGAR |
| SC 13G/A | 2022-12-23 | ELI LILLY & Co | ProQR Therapeutics N.V. | 13,371,562 | 16.6% | EDGAR |
| SC 13D/A | 2022-12-01 | ELI LILLY & Co | Akouos, Inc. | 100 | 100.0% | EDGAR |
| SC 13D | 2022-10-27 | ELI LILLY & Co | Akouos, Inc. | 9,639,189 | 25.5% | EDGAR |
| SC 13G/A | 2022-02-11 | PNC FINANCIAL SERVICES GROUP, INC. | ELI LILLY & Co | 51,888,455 | 5.4% | EDGAR |
| SC 13G/A | 2022-02-10 | ELI LILLY & Co | Aeglea BioTherapeutics, Inc. | 1,526,516 | 3.1% | EDGAR |
| SC 13G/A | 2022-02-10 | ELI LILLY & Co | LEAP THERAPEUTICS, INC. | 3,151,605 | 3.5% | EDGAR |
| SC 13G/A | 2022-02-10 | ELI LILLY & Co | Avidity Biosciences, Inc. | 2,319,396 | 4.9% | EDGAR |
| SC 13G/A | 2022-02-10 | ELI LILLY & Co | Surface Oncology, Inc. | 1,593,997 | 3.5% | EDGAR |